Stevanato Group S.p.A. Ordinary Shares (STVN)
19.65
+0.00 (0.00%)
NYSE· Last Trade: Aug 5th, 8:47 AM EDT
Revenue grew 8% as high-value solutions surged 16%, driving adjusted EBITDA up 21%.
Via The Motley Fool · August 4, 2026
Stevanato Group (NYSE:STVN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
Via Benzinga · August 4, 2026
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Via The Motley Fool · June 9, 2026
Stevanato (STVN) Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends to retire. The decline, which wiped out significant market capitalization in a single session, reflects investor anxiety over the
Via MarketMinute · March 11, 2026

Stevanato (STVN) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 4, 2026
Date: December 23, 2025 Introduction In the high-stakes world of biotechnology and pharmaceutical manufacturing, few companies are as indispensable yet as quietly influential as West Pharmaceutical Services (NYSE: WST). Headquartered in Exton, Pennsylvania, West is a global leader in the design and production of technologically advanced containment and delivery systems for injectable drugs. While the [...]
Via PredictStreet · December 23, 2025
As the pharmaceutical industry undergoes its most significant transformation in decades, the spotlight often falls on the blockbuster drugs themselves—the weight-loss miracles and the life-saving biologics. However, a quieter, equally vital revolution is happening in the delivery systems that bring these treatments to patients. West Pharmaceutical Services (NYSE: WST)
Via MarketMinute · December 23, 2025
Stevanato (STVN) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 6, 2025
Stevanato Group (STVN) beat Q3 2025 earnings and revenue estimates, driven by record high-value solutions and strong demand for its syringes.
Via Chartmill · November 6, 2025
Via Benzinga · April 7, 2025
Via Benzinga · April 4, 2025

Via Benzinga · February 14, 2025

Via Benzinga · February 14, 2025

Via Benzinga · December 31, 2024

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
Via Benzinga · December 15, 2024

Via Benzinga · December 5, 2024

Top performing mid-cap stocks in the last week, including Semtech, Stevanato, Ambarella, Ardent Health, BILL, Box, and Grupo Financiero Galicia.
Via Benzinga · September 2, 2024


